Portal de investigação
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Dados básicos
- Código:
- Estudo Observacional Académico (4WARD)
- Protocolo:
- Estudo Observacional Académico (4WARD)
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2021
- Ano de conclusão:
Objectivos do projeto
Tipo de Estudo: Estudo Observacional – Iniciativa do Investigador; Subtipo: Outro; Fase: Cross-sectional; Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Unicêntrico - Cuidados Secundários - Centros de Ensaio: CHUSJ - Doença investigada: Doença Inflamatória Intestinal – Participantes recrutados: 30;
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
Estevinho, Maria Manuela; (...); Magro, Fernando
Review. 10.1177/17562848221142673. 2022
A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn's disease prognosis - a prospective study
Magro, F.; (...); Dias, C. C.
Meeting Abstract. 2023
Accuracy of information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO guidelines
Farrugia, Y.; (...); Ellul, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae040. 2024
Active pharmacovigilance project in a tertiary hospital
Souto, Miguel Torre; (...); Reina-Couto, Marta
Meeting Abstract. 2023
Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Magro, F.; (...); Feagan, B. G.
Meeting Abstract. 2023
ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Magro, FERNANDO; (...); Feagan, Brian G.
Meeting Abstract. 2023
Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study
Abreu, C; (...); Magro, F
Article. 10.3390/vaccines11030703. 2023
Adherence to Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Two-Year Prospective Portuguese Cohort Study.
Abreu, C; (...); Magro, F
Article. 2023
Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?
Ministro, P; (...); Magro, F.
Article. 10.14309/ctg.0000000000000309. 2021
Aminosalicylates and COVID-19: Facts or Coincidences?
Magro, F., Dias, C., Morato, M.
Letter. 10.1053/j.gastro.2020.05.092. 2021
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
D'Amico, Ferdinando; (...); Allocca, Mariangela
Article. 10.1111/eci.14283. 2024
Analysis of clinical features associated with favourable outcomes from ustekinumab treat-totarget strategy in Crohn's Disease patients in the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 10.1093/ecco-jcc/jjab075.039. 2021
Angiotensin-converting enzymes 1 and 2 in the feces: presence and catalytic activity in the rat 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis
Ferreira Duarte, M; (...); Morato, M
Article. 10.1111/jgh.16541. 2024
Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations
Schreiber, S. W.; (...); Peyrin-Biroulet, L.
Meeting Abstract. 2023
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Dubinsky, Marla C.; (...); Regueiro, Miguel
Article. 10.1093/ibd/izac061. 2023
Association of Gut Microbiome and Dipeptidyl Peptidase 4 in Immune-Mediated Inflammatory Bowel Disease: A Rapid Literature Review
Gomes, SF; (...); Magro, F
Review. 10.3390/ijms252312852. 2024
Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease
Magro, F.; (...); Reinisch, W.
Meeting Abstract. 2022
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
Magro, FERNANDO; (...); Reinisch, Walter
Meeting Abstract. 10.1136/gutjnl-2022-BSG.74. 2022
Author's Reply: ``Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?''
Sousa, Paula, Magro, Fernando
Editorial Material. 10.1016/j.dld.2023.12.006. 2024
Benefit-Risk Trade-offs and Patient Preferences for Therapy Selection in Ulcerative Colitis: a Multicountry Preference Study
Gisbert, Javier P.; (...); Vermeire, Severine
Article. 10.1093/ibd/izae162. 2024
Benefit-risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study
Gisbert, J. P.; (...); Vermeire, S.
Meeting Abstract. 2024
Bile salts and proinflammatory cytokines inhibit MCT1-mediated cellular uptake of butyrate and interfere with its antiproliferative properties
Couto, MR; (...); Martel, F.
Article. 10.1016/j.yexcr.2023.113670. 2023
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus
D'Amico, F; (...); Danese, S
Review. 10.1016/j.autrev.2021.102849. 2021
Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
Magro, F.; (...); Correia, L.
Meeting Abstract. 2021
Burden of Disease and Cost of Illness of Inflammatory Bowel Diseases in Portugal
Magro, FERNANDO; (...); Correia, Luis
Article. 10.1159/000525206. 2023
CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
Peyrin-Biroulet, Laurent; (...); Danese, Silvio
Meeting Abstract. 2022
CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL
Danese, Silvio; (...); Peyrin-Biroulet, Laurent
Meeting Abstract. 2021
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Peyrin-Biroulet, Laurent; (...); Danese, Silvio
Article. 10.1111/apt.17751. 2024
Clinical Trials in Portugal: Past and Future. Position Paper from the Colleges of Clinical Pharmacology and Pharmaceutical Medicine
Borges-Carneiro, Filipa; (...); Magro, FERNANDO
Editorial Material. 10.20344/amp.21371. 2024
Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis
Magro, F; (...); Peyrin-Biroulet, L
Review. 10.1093/ecco-jcc/jjaa176. 2021
Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis (vol 15, pg 551, 2021)
Vermeire, Severine; (...); Danese, Silvio
Correction. 2021
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
Allocca, Mariangela; (...); Fiorino, Gionata
Article. 10.1002/ueg2.12492. 2024
Composite outcomes in Crohn's disease: a systematic review and meta-analysis of observational studies
Estevinho, M. M.; (...); Magro, F.
Meeting Abstract. 2022
Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis
Magro, F; (...); Moreira, PL
Review. 10.1177/17562848221092754. 2022
Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis
Magro, F; (...); Moreira, P
Review. 10.1002/ueg2.12183. 2022
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
Ma, C; (...); Jairath, V
Article. 10.1053/j.gastro.2022.06.068. 2022
COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology
Magro, F.; (...); Siau, K
Review. 10.1002/ueg2.12115. 2021
COVID-19 Vaccines in IBD Patients: Particularities and Future Perspectives
Magro, Fernando, Estevinho, Maria Manuela
Editorial Material. 10.1093/ecco-jcc/jjac042. 2022
Changing paradigms in management of inflammatory bowel disease
Mao, Ren, Magro, Fernando
Editorial Material. 10.1002/ueg2.12347. 2022
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations
Schreiber, S; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjad130. 2023
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Parigi, TL; (...); Peyrin-Biroulet, L
Review. 10.1002/ueg2.12671. 2024
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
Caron, B; (...); Peyrin-Biroulet, L
Review. 10.1002/ueg2.12283. 2022
Definitions of Histological Abnormalities in Inflammatory Bowel Disease: an ECCO Position Paper
Feakins, R; (...); Rosini, F
Article. 10.1093/ecco-jcc/jjad142. 2023
Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper
Rosini, F.; (...); Svrcek, M.
Meeting Abstract. 2024
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis
Rubin, David T.; (...); Peyrin-Biroulet, Laurent
Article. 10.1093/ibd/izae204. 2024
Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
Peyrin-Biroulet, L; (...); Kubassova, O
Meeting Abstract. 2023
DEPLOYMENT OF AN ARTIFICIAL INTELLIGENCE TOOL FOR PRECISION MEDICINE IN ULCERATIVE COLITIS: PRELIMINARY DATA FROM 8 GLOBALLY DISTRIBUTED CLINICAL SITES
Rubin, David T.; (...); Kubassova, Olga
Meeting Abstract. 2023
Diagnostic Yield of Next-Generation Sequencing in Very Early-Onset Inflammatory Bowel Diseases: A Multicenter Study (vol 12, pg 1104, 2021)
Charbit-Henrion, F; (...); Cerf-Bensussan, N
Correction. 10.1093/ecco-jcc/jjaa164. 2021
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey
Parigi, TL; (...); Danese, S
Letter. 10.1016/S2468-1253(22)00085-1. 2022
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Parigi, TL; (...); Danese, S
Review. 10.1016/S2468-1253(23)00154-1. 2023
Dipeptidyl peptidase 4 (DPP4) in fecal samples: validation of the extraction methodology and stability in short-term storage conditions
Gomes, SF; (...); Magro, F
Article. 10.1515/cclm-2023-0139. 2023
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
D'Amico, F; (...); Danese, S
Review. 10.1093/ibd/izad159. 2023
Dose optimisation for Loss of Response to Vedolizumab - Pharmacokinetics and Immune Mechanisms
Ungar, B; (...); Ben Horin, S
Article. 10.1093/ecco-jcc/jjab067. 2021
Drug Prescribing Analysis: The Burden Of Orphan Drugs In A Tertiary Hospital Budget
Lopes, Diogo Jose; (...); Reina-Couto, Marta
Meeting Abstract. 2023
Early Disease Clearance With Etrasimod and Correlation With Week 52 Outcomes and Biomarkers: A Post Hoc Analysis of the Phase 3 ELEVATE UC Trials
Magro, FERNANDO; (...); Feagan, Brian G.
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Magro, FERNANDO; (...); Peyrin-Biroulet, Laurent
Meeting Abstract. 2023
EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Magro, F.; (...); Daperno, M.
Meeting Abstract. 2024
ECCO Governing Board European Crohn's and Colitis Organisation - ECCO, Ungargasse 6/13, A-1030 Vienna, Austria
Peyrin-Biroulet, Laurent; (...); Armuzzi, Alessandro
Letter. 10.1093/ecco-jcc/jjab225. 2022
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Kucharzik, T; (...); Vavricka, S
Editorial Material. 10.1093/ecco-jcc/jjab052. 2021
ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology
Magro, F; (...); Feakins, R
Article. 10.1093/ecco-jcc/jjac006. 2022
Editorial: elderly onset inflammatory bowel disease --clues from the largest population--based cohort study
Estevinho, MM, Magro, F
Editorial Material. 10.1111/apt.17543. 2023
Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 10.1093/ecco-jcc/jjab075.034. 2021
Effect of Toll-like receptor-2, -4, -5, -7, and NOD2stimulation on potassium channel conductance in intestinal epithelial cells (vol 323, pg G410, 2022)
Cosme, D., Soares-da-Silva, P., Magro, F.
Correction. 10.1152/ajpgi.00139.2023_COR. 2023
Effect of Toll-like receptor-2,-4,-5,-7, and NOD2 stimulation on potassium channel conductance in intestinal epithelial cells
Cosme, Dina, Soares-da-Silva, Patricio, Magro, Fernando
Article. 10.1152/ajpgi.00139.2022. 2022
EFFECT OF UPADACITINIB ON INFLAMMATORY MARKERS AND CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE IN THE PHASE 3, U-EXCEL, U-EXCEED, AND U-ENDURE STUDIES
Vermeire, Severine; (...); Peyrin-Biroulet, Laurent
Meeting Abstract. 2023
Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Vermeire, S.; (...); Peyrin-Biroulet, L.
Meeting Abstract. 2023
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study
Albshesh, A; (...); Kopylov, U
Article. 10.3390/jcm10132914. 2021
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
Magro, Fernando; (...); Reinisch, Walter
Article. 10.1016/j.cgh.2023.11.010. 2024
Efficacy and safety of probiotics in inflammatory bowel disease: an umbrella review and updated meta-analysis of randomized controlled trials
Estevinho, M. M.; (...); Magro, F.
Meeting Abstract. 2024
Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension
D'Haens, G.; (...); Blumenstein, I.
Meeting Abstract. 2024
Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial
Peyrin-Biroulet, L; (...); Danese, S
Meeting Abstract. 2022
EFFICACY OF THE TREAT-TO-TARGET APPROACH IN MODIFYING DISEASE COURSE WITH USTEKINUMAB IN PATIENTS WITH MODERATETO-SEVERE CROHN'S DISEASE: RESULTS FROM THE STARDUST TRIAL
Peyrin-Biroulet, Laurent; (...); Danese, Silvio
Meeting Abstract. 2022
Efficacy of Upadacitinib in Patients With One or More Prior Surgical Procedures for Crohn's Disease: A Post Hoc Analysis of U-EXCEL, U-EXCEED, and U-ENDURE Phase 3 Trials
Loftus, E; (...); Lichtenstein, G
Meeting Abstract. 10.14309/01.ajg.0000995764.89379.2a. 2023
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
Guillo, L; (...); Peyrin-Biroulet, L
Review. 10.1016/S2468-1253(21)00297-1. 2022
Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis
Estevinho, Maria Manuela, Magro, Fernando
Letter. 10.1016/j.cgh.2021.08.003. 2022
Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review (vol 14, pg 688, 2020)
Magro, F; (...); Peyrin-Biroulet, L
Correction. 2021
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Pinto Lopes, P; (...); Magro, F.
Article. 10.14309/ctg.0000000000000320. 2021
Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue
De Sousa, HT, Gullo, I, Magro, FERNANDO
Letter. 10.1016/j.cgh.2022.06.023. 2023
Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
De Sousa, H. Tavares; (...); Magro, F.
Meeting Abstract. 2024
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis
Magro, F; (...); Santiago, M
Review. 10.1002/ueg2.12366. 2023
Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials
Pai, Rish K.; (...); Magro, FERNANDO
Review. 10.1080/17474124.2024.2326838. 2024
Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease
Reinisch, W.; (...); Pai, R.
Meeting Abstract. 2022
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Magro, F.; (...); Carneiro, F.
Article. 10.1016/j.cgh.2020.09.017. 2021
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study
Magro, F; (...); Dias, CC
Article. 10.1002/ueg2.12420. 2023
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease
Peyrin-Biroulet, L; (...); Beaugerie, L
Article. 10.1016/j.cgh.2022.09.018. 2023
Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype
de Sousa, HT; (...); Magro, F
Article. 10.14309/ctg.0000000000000330. 2021
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis
Roseira, Joana; (...); Magro, Fernando
Review. 10.1093/ibd/izac203. 2023
Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn's disease
Pai, Rish; (...); Dhesi, Endip
Meeting Abstract. 10.1136/gutjnl-2023-BSG.370. 2023
Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
Pai, R.; (...); Magro, F.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.519. 2021
Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn's Disease
Pai, Rish; (...); Magro, FERNANDO
Meeting Abstract. 2021
Impact of mirikizumab therapy on histological measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
Leong, R.; (...); Magro, F.
Meeting Abstract. 2022
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Solitano, Virginia; (...); Danese, Silvio
Review. 10.1016/j.autrev.2023.103504. 2024
Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?
Santiago, M; (...); Magro, F
Article. 10.14309/ctg.0000000000000481. 2022
Inflammation of the appendix in ulcerative colitis - Does it have a predictive value?
Magro, F, Estevinho, MM, Feakins, R
Editorial Material. 10.1002/ueg2.12181. 2021
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce (vol 14, pg s798, 2020)
Magro, F.; (...); Peyrin-Biroulet, L.
Correction. 2021
Infrared furnace for in situ neutron single-crystal diffraction studies in controlled gas atmospheres at high temperatures
Magro, FERNANDO; (...); Paulus, Werner
Article. 10.1107/S1600576721003198. 2021
Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis
Ferreira-Duarte, M; (...); Morato, M
Article. 10.3390/ijms22094836. 2021
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
Caron, B; (...); Peyrin-Biroulet, L
Review. 10.3390/medicina59010183. 2023
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
D'Amico, F; (...); Peyrin-Biroulet, L
Article. 10.1002/ueg2.12069. 2021
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Olivera, PA; (...); Peyrin-Biroulet, L
Article. 10.1038/s41575-021-00492-8. 2021
Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 a) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis
Poenariu, Ioan Sabin; (...); Estevinho, Maria Manuela
Article. 10.3390/biomedicines11123137. 2023
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
Caron, B; (...); Peyrin-Biroulet, L
Article. 10.1016/j.cgh.2022.02.032. 2022
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
D'Amico, Ferdinando; (...); Danese, Silvio
Review. 10.3390/jcm12031142. 2023
Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results
D'Amico, F.; (...); Dignass, A.
Meeting Abstract. 2024
Long-term effect of Toll-like receptor-2,-4,-5,-7 and NOD2 stimulation on Na plus , K plus -ATPase activity and expression in intestinal epithelial cells
Cosme, D, soares-da-silva, p, Magro, F
Article. 10.1152/ajpcell.00208.2022. 2023
Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?
Magro, Fernando, Estevinho, Maria Manuela, Valois, Andre
Article. 10.1093/jcag/gwad034. 2023
Microbiota therapeutics for inflammatory bowel disease: the way forward
Bethlehem, Lukas; (...); Colombel, Jean-Frederic
Article. 10.1016/S2468-1253(23)00441-7. 2024
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
Louis, E; (...); Travis, SP
Article. 10.1136/bmjgast-2021-000853. 2022
Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib
Magro, F.; (...); Reinisch, W.
Meeting Abstract. 2024
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Dignass, Axel U.; (...); Travis, Simon P. L.
Article. 10.1080/00365521.2021.2015801. 2022
Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients
Fernandes, BM; (...); Bernardes, J.
Article. 2022
Musculoskeletal manifestations in a Portuguese cohort of 235 inflammatory bowel disease patients
Fernandes, B. M.; (...); Bernardes, M.
Article. 2022
Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
Temido, Maria Jose; (...); Peyrin-Biroulet, Laurent
Editorial Material. 10.1093/ecco-jcc/jjae136. 2024
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis
Estevinho, Maria Manuela; (...); Magro, Fernando
Review. 10.1111/apt.18315. 2024
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Olivera, PA; (...); Peyrin-Biroulet, L
Review. 10.1093/ecco-jcc/jjac133. 2023
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Schreiber, S; (...); Reinisch, W
Review. 10.1007/s12325-021-01990-6. 2022
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era (Jan, 10.1007/s12325-021-01990-6, 2022)
Schreiber, S; (...); Reinisch, W
Correction. 10.1007/s12325-022-02082-9. 2022
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
D'Haens, Geert R.; (...); Peyrin-Biroulet, Laurent
Meeting Abstract. 2021
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Imbrizi, M, Magro, F, Coy, CSR
Review. 10.3390/ph16091272. 2023
Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
Martins, A; (...); de Abreu, CMF
Meeting Abstract. 2023
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
D'Amico, F; (...); Danese, S
Review. 10.1093/ecco-jcc/jjab206. 2022
Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review
Cosme, D; (...); Magro, F
Review. 10.1152/ajpcell.00393.2020. 2021
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
D'Amico, F; (...); Danese, S
Article. 10.3390/jcm12196350. 2023
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
D'Amico, Ferdinando; (...); Danese, Silvio
Review. 10.1080/17474124.2024.2397650. 2024
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus
Fantini, Massimo Claudio; (...); Ghosh, Subrata
Article. 10.1093/ecco-jcc/jjae026. 2024
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD international consensus
Fantini, M. C.; (...); Ghosh, S.
Meeting Abstract. 2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Olivera, Pablo A.; (...); Peyrin-Biroulet, Laurent
Article. 10.1016/j.dld.2024.03.010. 2024
Proactive Infliximab monitoring improves the rates of transmural remission in Crohn's disease - a propensity score matched analysis
Fernandes, S. R.; (...); Magro, F.
Meeting Abstract. 2024
Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn's Disease: A Propensity Score-Matched Analysis
Fernandes, SR; (...); Magro, F
Article. 10.1093/ibd/izad272. 2023
Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study
Dignass, A.; (...); Leitner, C.
Meeting Abstract. 2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study
D'Amico, Ferdinando; (...); Dignass, Axel
Article. 10.1002/ueg2.12572. 2024
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
Magalhaes, Diogo; (...); GEDII
Review. 10.1177/17562848231155987. 2023
Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
Magro, F, Estevinho, MM
Editorial Material. 10.1002/ueg2.12432. 2023
Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
Magro, F; (...); Peyrin-Biroulet, L
Article. 10.1093/ecco-jcc/jjad050. 2023
Safety and efficacy of MH002, an optimized live biotherapeutic product, for the treatment of mild to moderate ulcerative colitis: a first-in-disease, double-blind, randomized clinical trial
Vermeire, S.; (...); Bolca, S.
Meeting Abstract. 2024
Short Inflammatory Bowel Disease Questionnaire: translation and validation to the Portuguese language
Roseira, Joana; (...); Magro, Fernando
Article. 10.1186/s12955-021-01698-9. 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Magro, F; (...); Dias, CC
Article. 10.1016/j.cgh.2021.12.004. 2022
SUBCLINICAL PERSISTENT INFLAMMATION AS RISK FACTOR FOR CROHN'S DISEASE PROGRESSION: FINDINGS FROM A PROSPECTIVE REAL-WORLD STUDY OF 2 YEARS
Magro, FERNANDO; (...); Dias, Camila
Meeting Abstract. 2022
The degree of bowel remission predicts phenotype progression in Crohn's disease
Fernandes, Samuel Raimundo; (...); Magro, FERNANDO
Article. 10.1002/ueg2.12581. 2024
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Cheon, Jae Hee; (...); Travis, Simon Pl
Article. 10.5217/ir.2022.00006. 2022
The importance of a Clinical Pharmacology Unit to a Pharmacy and Therapeutics Committee, in a tertiary hospital
Borges-Carneiro, Filipa; (...); Magro, FERNANDO
Meeting Abstract. 2023
The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients
Magro, F.; (...); Santiago, M.
Meeting Abstract. 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
Magro, Fernando; (...); Santiago, Mafalda
Article. 10.1093/ecco-jcc/jjae014. 2024
The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review
Santiago, M; (...); Magro, F
Review. 10.1093/ibd/izab334. 2022
The Process of Developing a Disease Activity Index in Microscopic Colitis
Lesnovska, Katarina Pihl; (...); Hjortswang, Henrik
Article. 10.1093/ecco-jcc/jjab170. 2022
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
Sousa, P; (...); Magro, F
Article. 10.1016/j.dld.2023.10.027. 2024
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease
Sousa, P; (...); Magro, F
Article. 10.1016/j.dld.2021.05.038. 2021
Thiopurines: use them or lose them? Results of an international survey
Sousa, P. C.; (...); Magro, F.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.531. 2021
Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease
Fernandes, SR; (...); Magro, F
Article. 10.1002/ueg2.12497. 2023
Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties (vol 14, pg 743, 2020)
de Sousa, HT; (...); Magro, F
Correction. 2021
Transmural Remission Associates with a Lower Risk of Phenotype Progression in Crohn's Disease
Fernandes, S. R.; (...); Magro, F.
Meeting Abstract. 2024
Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
Fernandes, Samuel Raimundo; (...); Magro, FERNANDO
Article. 10.1002/ueg2.12356. 2023
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
Danese, S; (...); Peyrin-Biroulet, L
Article. 10.1016/S2468-1253(21)00474-X. 2022
UEG journal: The voice of European Gastroenterology
Meining, Alexander G., Magro, Fernando, Drenth, Joost P. H.
Editorial Material. 10.1002/ueg2.12264. 2022
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study
D'Amico, Ferdinando; (...); Danese, Silvio
Article. 10.1002/ueg2.12288. 2022
Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results
Dignass, A.; (...); Magro, F.
Meeting Abstract. 2024
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
Danese, Silvio; (...); Peyrin-Biroulet, Laurent
Meeting Abstract. 2021
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial
Panés, J; (...); Dignass, A
Article. 10.1002/ueg2.12384. 2023
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial
Danese, S; (...); Peyrin-Biroulet, L
Meeting Abstract. 10.1093/ecco-jcc/jjab076.425. 2021
Vaccines - beliefs and concerns: the voice of patients with inflammatory immunomediated diseases
Abreu, C; (...); Magro, F
Article. 10.1097/MEG.0000000000002589. 2023
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis (vol 14, pg 1066, 2020)
Vermeire, Severine; (...); Danese, Silvio
Correction. 2021
Viable Mycobacterium avium subsp. paratuberculosis Colonizes Peripheral Blood of Inflammatory Bowel Disease Patients
Estevinho, MM; (...); Sarmento, A
Article. 10.3390/microorganisms11061520. 2023
